Landscape Capital Management L.L.C. Makes New $710,000 Investment in Vaxcyte, Inc. $PCVX

Landscape Capital Management L.L.C. purchased a new stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) in the second quarter, HoldingsChannel reports. The firm purchased 12,211 shares of the company’s stock, valued at approximately $710,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Smartleaf Asset Management LLC boosted its position in shares of Vaxcyte by 156.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 597 shares of the company’s stock worth $27,000 after purchasing an additional 364 shares during the period. Caitong International Asset Management Co. Ltd increased its holdings in Vaxcyte by 1,463.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company’s stock valued at $30,000 after purchasing an additional 600 shares during the last quarter. EverSource Wealth Advisors LLC raised its position in Vaxcyte by 33.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock valued at $34,000 after purchasing an additional 184 shares during the period. CIBC Private Wealth Group LLC raised its position in Vaxcyte by 22,500.0% in the third quarter. CIBC Private Wealth Group LLC now owns 1,356 shares of the company’s stock valued at $49,000 after purchasing an additional 1,350 shares during the period. Finally, Capital Advisors Ltd. LLC purchased a new stake in Vaxcyte in the first quarter valued at approximately $58,000. 96.78% of the stock is owned by hedge funds and other institutional investors.

Vaxcyte Stock Performance

NASDAQ PCVX opened at $62.62 on Monday. The firm has a market cap of $9.32 billion, a price-to-earnings ratio of -8.21 and a beta of 1.23. The firm has a 50 day simple moving average of $56.43 and a 200-day simple moving average of $55.79. Vaxcyte, Inc. has a one year low of $29.87 and a one year high of $65.00.

Vaxcyte (NASDAQ:PCVX) last announced its earnings results on Wednesday, August 5th. The company reported ($1.97) earnings per share for the quarter, topping the consensus estimate of ($2.06) by $0.09. During the same quarter in the previous year, the company earned ($1.22) EPS. Equities analysts predict that Vaxcyte, Inc. will post -7.6 EPS for the current fiscal year.

Insider Buying and Selling at Vaxcyte

In other Vaxcyte news, insider Harpreet S. Dhaliwal sold 17,000 shares of the business’s stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $55.00, for a total value of $935,000.00. Following the completion of the transaction, the insider owned 76,756 shares in the company, valued at $4,221,580. The trade was a 18.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Jim Wassil sold 2,250 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $49.52, for a total value of $111,420.00. Following the sale, the chief operating officer directly owned 158,494 shares in the company, valued at $7,848,622.88. This represents a 1.40% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 120,646 shares of company stock worth $6,570,810. 3.30% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms have commented on PCVX. Zacks Research upgraded Vaxcyte from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th. Wall Street Zen raised Vaxcyte from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 8th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Vaxcyte in a report on Monday, July 6th. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $86.00.

Vaxcyte Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.